{"id":21824,"date":"2026-05-18T11:56:31","date_gmt":"2026-05-18T11:56:31","guid":{"rendered":"https:\/\/www.quantumrun.com\/consulting\/?p=21824"},"modified":"2026-05-18T11:57:27","modified_gmt":"2026-05-18T11:57:27","slug":"johnson-johnson-statistics","status":"publish","type":"post","link":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/","title":{"rendered":"Johnson &amp; Johnson Statistics 2026: Revenue Growth, Dividends And Workforce Data"},"content":{"rendered":"\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Inter:wght@400;500;600&#038;display=swap\" rel=\"stylesheet\">\n<script src=\"https:\/\/cdn.jsdelivr.net\/npm\/chart.js\"><\/script>\n<style>\n.cbg-article .meta{text-align:center;color:#555;margin-bottom:14px;font-size:15px;}\n.cbg-article a{color:#1a4fbf;text-decoration:none;border-bottom:1px solid #d6def0;}\n.cbg-article a:hover{border-bottom-color:#1a4fbf;}\n.cbg-article details{border-bottom:1px solid #e5e5e5;padding:14px 0;}\n.cbg-article details:first-of-type{border-top:1px solid #e5e5e5;}\n.cbg-article summary{cursor:pointer;font-weight:500;padding:6px 0;list-style:none;font-size:17px;position:relative;padding-right:28px;}\n.cbg-article summary::-webkit-details-marker{display:none;}\n.cbg-article summary::after{content:'+';position:absolute;right:0;top:6px;font-size:22px;color:#555;}\n.cbg-article details[open] summary::after{content:'\\2212';}\n.cbg-article details p{padding-top:10px;margin-bottom:0;color:#333;}\n.cbg-article table{width:100%;border-collapse:collapse;margin:18px 0 10px;}\n.cbg-article th{background:#f5f5f5;font-weight:600;text-align:center;padding:10px 12px;border:1px solid #e0e0e0;font-size:15px;}\n.cbg-article td{text-align:center;padding:9px 12px;border:1px solid #e0e0e0;font-size:15px;}\n.cbg-article .source-line{font-size:13px;color:#777;margin:4px 0 18px;}\n.cbg-article .chart-wrap{max-width:680px;margin:20px auto;position:relative; height: 400px;\n    display: flex;\n    justify-content: center;\n    align-items: center;\n}\n<\/style>\n<div class=\"cbg-article\">\n<p>Johnson &#038; Johnson closed FY2025 with $94.2 billion in total sales, up 6.0% from the prior year, and posted its strongest single quarter ever in Q4 at $24.6 billion. The company now targets crossing $100 billion in annual revenue for the first time in FY2026. Here is a full breakdown of J&#038;J&#8217;s latest financials, segment performance, key products, and pipeline as of early 2026.<\/p>\n\n<h2>Johnson &#038; Johnson Statistics 2026 &#8211; TL;DR<\/h2>\n<p>J&#038;J recorded $94,193 million in FY2025 total sales, a 6.0% year-on-year increase from $88,821 million in FY2024.<\/p>\n<p>The Innovative Medicine segment brought in $60,401 million (64.1% of total revenue); MedTech added $33,792 million (35.9%).<\/p>\n<p>Q4 2025 was J&#038;J&#8217;s highest-revenue quarter ever at $24,564 million, growing 9.1% year on year.<\/p>\n<p>J&#038;J reported 28 individual products each generating over $1 billion in annual sales.<\/p>\n<p>Management has guided for FY2026 revenue above $100 billion for the first time in company history.<\/p>\n\n<h2>How Much Revenue Did Johnson &#038; Johnson Generate in FY2025?<\/h2>\n<p>Johnson &#038; Johnson reported full-year 2025 sales of $94,193 million, up from $88,821 million in FY2024 and $85,159 million in FY2023. That 6.0% reported increase (5.3% on an operational basis, stripping out currency effects) came after the 2023 Kenvue spin-off removed J&#038;J&#8217;s consumer health division entirely. The company is now a two-segment operation: pharmaceuticals and medical devices.<\/p>\n<p>Gross profit for FY2025 reached $63,937 million, though gross margin dipped slightly to 67.9% from 69.1% a year earlier. Free cash flow came in at roughly $19.7 billion, or about 20.9% of revenue. Return on equity stood at 32.9%.<\/p>\n<table>\n<tr><th>Metric<\/th><th>FY2025<\/th><th>FY2024<\/th><th>FY2023<\/th><\/tr>\n<tr><td>Total Sales<\/td><td>$94,193M<\/td><td>$88,821M<\/td><td>$85,159M<\/td><\/tr>\n<tr><td>Gross Profit<\/td><td>$63,937M<\/td><td>$61,350M<\/td><td>$58,606M<\/td><\/tr>\n<tr><td>Gross Margin<\/td><td>67.9%<\/td><td>69.1%<\/td><td>68.8%<\/td><\/tr>\n<tr><td>R&#038;D Expense<\/td><td>$14,665M<\/td><td>$17,232M<\/td><td>$15,085M<\/td><\/tr>\n<tr><td>Selling, Marketing &#038; Admin<\/td><td>$23,676M<\/td><td>$22,869M<\/td><td>$21,512M<\/td><\/tr>\n<tr><td>Free Cash Flow<\/td><td>~$19.7B<\/td><td>&#8211;<\/td><td>&#8211;<\/td><\/tr>\n<\/table>\n<p class=\"source-line\">Source: Johnson &#038; Johnson Form 10-K FY2025 (SEC EDGAR); J&#038;J Q4\/Full-Year 2025 press release (January 21, 2026)<\/p>\n<div class=\"chart-wrap\"><canvas id=\"revenueChart\"><\/canvas><\/div>\n<p>R&#038;D spending fell from $17,232 million in FY2024 to $14,665 million in FY2025 \u2014 a 14.9% drop. That decline doesn&#8217;t reflect a real pullback in research spending. FY2024&#8217;s figure was inflated by large in-process R&#038;D charges and acquisition-related impairments. In-process R&#038;D impairments alone dropped from $211 million to $81 million year over year. At 15.6% of sales, FY2025 R&#038;D sits closer to J&#038;J&#8217;s historical norm.<\/p>\n\n<h2>Johnson &#038; Johnson Revenue by Segment<\/h2>\n<p>After the Kenvue consumer health separation, J&#038;J runs two segments. Innovative Medicine (pharmaceuticals) generated $60,401 million in FY2025, growing 6.0% reported and 5.3% operationally. MedTech (medical devices) hit $33,792 million, up 6.1% reported and 5.4% operationally. The split works out to roughly 64\/36 in favor of pharmaceuticals.<\/p>\n<table>\n<tr><th>Segment<\/th><th>FY2025 Sales<\/th><th>FY2024 Sales<\/th><th>YoY Change<\/th><th>% of Total<\/th><\/tr>\n<tr><td>Innovative Medicine<\/td><td>$60,401M<\/td><td>$56,964M<\/td><td>+6.0%<\/td><td>64.1%<\/td><\/tr>\n<tr><td>MedTech<\/td><td>$33,792M<\/td><td>$31,857M<\/td><td>+6.1%<\/td><td>35.9%<\/td><\/tr>\n<tr><td>Total<\/td><td>$94,193M<\/td><td>$88,821M<\/td><td>+6.0%<\/td><td>100%<\/td><\/tr>\n<\/table>\n<p class=\"source-line\">Source: Johnson &#038; Johnson Form 8-K Q4\/Full-Year 2025 (SEC EDGAR)<\/p>\n<div class=\"chart-wrap\"><canvas id=\"segmentPie\"><\/canvas><\/div>\n\n<h2>Johnson &#038; Johnson Quarterly Revenue (FY2025)<\/h2>\n<p>Revenue accelerated through each quarter of FY2025. Q1 grew 2.4%, Q2 picked up to 5.8%, Q3 hit 6.8%, and Q4 surged to 9.1%. That Q4 figure \u2014 $24,564 million \u2014 was the highest single-quarter revenue in J&#038;J&#8217;s history. Innovative Medicine drove the Q4 acceleration, posting $15,763 million at a 10.0% reported growth rate, its fastest quarterly clip of the year.<\/p>\n<table>\n<tr><th>Quarter<\/th><th>Total Sales<\/th><th>Innovative Medicine<\/th><th>MedTech<\/th><th>YoY Growth<\/th><\/tr>\n<tr><td>Q1 2025<\/td><td>$21,893M<\/td><td>$13,873M<\/td><td>$8,020M<\/td><td>+2.4%<\/td><\/tr>\n<tr><td>Q2 2025<\/td><td>$23,743M<\/td><td>$15,202M<\/td><td>$8,541M<\/td><td>+5.8%<\/td><\/tr>\n<tr><td>Q3 2025<\/td><td>$23,993M<\/td><td>$15,563M<\/td><td>$8,430M<\/td><td>+6.8%<\/td><\/tr>\n<tr><td>Q4 2025<\/td><td>$24,564M<\/td><td>$15,763M<\/td><td>$8,801M<\/td><td>+9.1%<\/td><\/tr>\n<\/table>\n<p class=\"source-line\">Source: Johnson &#038; Johnson Form 8-K filings Q1-Q4 2025 (SEC EDGAR)<\/p>\n<div class=\"chart-wrap\"><canvas id=\"quarterlyChart\"><\/canvas><\/div>\n<p>Q4 2025 net earnings hit $5,537 million, an 18.2% jump from $4,686 million in Q4 2024. Earnings growth outpaced the 9.1% revenue increase, pointing to margin improvement within the quarter. Diluted EPS for Q4 came in at $2.10 (GAAP), up 18.7% from $1.93 a year earlier. Adjusted Q4 EPS was $2.46.<\/p>\n\n<h2>Johnson &#038; Johnson EPS (FY2025)<\/h2>\n<p>Full-year diluted EPS (GAAP) reached $11.03, and adjusted EPS came in at $10.79. Both figures include a $0.10 negative impact from the Halda Therapeutics acquisition completed during the year. J&#038;J&#8217;s market capitalization stood above $560 billion in early 2026, making it the second-largest company globally in the pharma\/biotech space.<\/p>\n<table>\n<tr><th>EPS Metric<\/th><th>FY2025<\/th><th>Q4 2025<\/th><\/tr>\n<tr><td>Diluted EPS (GAAP)<\/td><td>$11.03<\/td><td>$2.10<\/td><\/tr>\n<tr><td>Adjusted EPS (non-GAAP)<\/td><td>$10.79<\/td><td>$2.46<\/td><\/tr>\n<\/table>\n<p class=\"source-line\">Source: Johnson &#038; Johnson Q4\/Full-Year 2025 press release (January 21, 2026)<\/p>\n\n<h2>What Are Johnson &#038; Johnson&#8217;s Top Products?<\/h2>\n<p>DARZALEX, J&#038;J&#8217;s multiple myeloma drug, has posted sales above $3 billion per quarter for three consecutive quarters through mid-2025. It remains the leading growth driver across the Innovative Medicine segment&#8217;s oncology portfolio. CARVYKTI (CAR-T cell therapy), ERLEADA (prostate cancer), and the newly launched RYBREVANT FASPRO plus LAZCLUZE combination for non-small cell lung cancer all contributed to oncology growth in FY2025.<\/p>\n<p>Outside oncology, TREMFYA led immunology growth, and SPRAVATO continued to gain ground in neuroscience. J&#038;J also added CAPLYTA \u2014 an adjunctive therapy for major depressive disorder approved by the FDA in FY2025 \u2014 to its portfolio. Across all therapeutic areas, J&#038;J now counts 28 individual products each exceeding $1 billion in annual sales, according to management comments on the Q4 2025 earnings call.<\/p>\n\n<h3>STELARA Loss of Exclusivity Impact<\/h3>\n<p>STELARA&#8217;s loss of exclusivity created a roughly 1,070 basis point headwind to Innovative Medicine growth in Q3 2025 alone. That means the segment grew about 5.3% operationally despite an underlying drag of approximately 10.7 percentage points from STELARA&#8217;s decline. Strip out that headwind and the segment would have grown around 16% operationally in Q3 \u2014 a number that shows just how much new product growth is compensating for the STELARA erosion.<\/p>\n<div class=\"chart-wrap\"><canvas id=\"stelaraChart\"><\/canvas><\/div>\n\n<h2>Johnson &#038; Johnson MedTech and Pipeline<\/h2>\n<p>The MedTech segment&#8217;s $33.8 billion in FY2025 revenue got a 1.1% boost from the Shockwave cardiovascular acquisition. J&#038;J also filed the submission for its OTTAVA robotic surgical system during FY2025, entering the surgical robotics space directly. MedTech&#8217;s Q4 performance at $8,801 million (up 7.5% year on year) was the segment&#8217;s strongest quarter of the year.<\/p>\n<p>J&#038;J&#8217;s pipeline includes over 200 drugs currently in development. For FY2026, management expects accelerated growth from both segments \u2014 Innovative Medicine driven by TREMFYA, DARZALEX, CARVYKTI, ERLEADA, and SPRAVATO, while MedTech growth should come from cardiovascular, surgery, and vision categories.<\/p>\n\n<h2>Johnson &#038; Johnson FY2026 Outlook<\/h2>\n<p>J&#038;J&#8217;s stated target is to exceed $100 billion in annual revenue for the first time in FY2026. Getting there from FY2025&#8217;s $94.2 billion base requires roughly $5.8 billion or more in incremental growth \u2014 a 6.2%+ increase. Given that Q4 2025 already showed 9.1% reported growth, that target appears within reach if the company maintains its current momentum.<\/p>\n<div class=\"chart-wrap\"><canvas id=\"outlookChart\"><\/canvas><\/div>\n\n<h2>FAQs<\/h2>\n<details>\n<summary>What was Johnson &#038; Johnson&#8217;s total revenue in FY2025?<\/summary>\n<p>Johnson &#038; Johnson reported $94,193 million ($94.2 billion) in total sales for FY2025, a 6.0% increase from $88,821 million in FY2024.<\/p>\n<\/details>\n<details>\n<summary>How many billion-dollar products does Johnson &#038; Johnson have?<\/summary>\n<p>J&#038;J disclosed 28 individual products each generating over $1 billion in annual sales, per the Q4 2025 earnings call in January 2026.<\/p>\n<\/details>\n<details>\n<summary>What is Johnson &#038; Johnson&#8217;s largest business segment?<\/summary>\n<p>Innovative Medicine (pharmaceuticals) is the largest segment at $60,401 million in FY2025 sales, accounting for 64.1% of total revenue.<\/p>\n<\/details>\n<details>\n<summary>Will Johnson &#038; Johnson exceed $100 billion in revenue?<\/summary>\n<p>Management has guided for FY2026 revenue above $100 billion. Reaching that target requires approximately 6.2% growth from FY2025&#8217;s $94.2 billion base.<\/p>\n<\/details>\n<details>\n<summary>What is Johnson &#038; Johnson&#8217;s market cap in 2026?<\/summary>\n<p>J&#038;J&#8217;s market capitalization exceeded $560 billion in early 2026, making it the second-largest pharma and biotech company globally.<\/p>\n<\/details>\n<p style=\"margin-top:32px;font-size:14px;color:#555;\">Sources:<\/p>\n<p style=\"font-size:14px;color:#555;\"><a href=\"https:\/\/investor.jnj.com\" rel=\"nofollow\" class=\"external\">https:\/\/investor.jnj.com<\/a><\/p>\n<p style=\"font-size:14px;color:#555;\"><a href=\"https:\/\/www.sec.gov\/cgi-bin\/browse-edgar?action=getcompany&#038;CIK=0000200406\" rel=\"nofollow\">https:\/\/www.sec.gov\/cgi-bin\/browse-edgar?action=getcompany&#038;CIK=0000200406<\/a><\/p>\n<p style=\"font-size:14px;color:#555;\"><a href=\"https:\/\/stocktitan.net\" rel=\"nofollow\" class=\"external\">https:\/\/stocktitan.net<\/a><\/p>\n<\/div>\n<script>\nvar colors={blue:'#2563eb',green:'#059669',orange:'#d97706',red:'#dc2626',slate:'#64748b',indigo:'#4f46e5',teal:'#0d9488'};\nnew Chart(document.getElementById('revenueChart'),{type:'bar',data:{labels:['FY2023','FY2024','FY2025'],datasets:[{label:'Total Sales ($ Billions)',data:[85.16,88.82,94.19],backgroundColor:[colors.slate,colors.blue,colors.indigo],borderRadius:4}]},options:{responsive:true,plugins:{legend:{display:false},title:{display:true,text:'Johnson & Johnson Annual Revenue (FY2023-FY2025)',font:{size:15,family:'Inter',weight:'600'},color:'#1a1a1a',padding:{bottom:14}}},scales:{y:{beginAtZero:false,min:80,ticks:{callback:function(v){return '$'+v+'B'},font:{family:'Inter'}},grid:{color:'#f0f0f0'}},x:{grid:{display:false},ticks:{font:{family:'Inter'}}}}}});\nnew Chart(document.getElementById('segmentPie'),{type:'doughnut',data:{labels:['Innovative Medicine','MedTech'],datasets:[{data:[60401,33792],backgroundColor:[colors.indigo,colors.teal],borderWidth:2,borderColor:'#fff'}]},options:{responsive:true,plugins:{legend:{position:'bottom',labels:{font:{family:'Inter',size:13},padding:16}},title:{display:true,text:'FY2025 Revenue by Segment ($ Millions)',font:{size:15,family:'Inter',weight:'600'},color:'#1a1a1a',padding:{bottom:10}}}}});\nnew Chart(document.getElementById('quarterlyChart'),{type:'line',data:{labels:['Q1 2025','Q2 2025','Q3 2025','Q4 2025'],datasets:[{label:'Total Sales ($M)',data:[21893,23743,23993,24564],borderColor:colors.indigo,backgroundColor:'rgba(79,70,229,0.08)',fill:true,tension:0.3,pointRadius:5,pointBackgroundColor:colors.indigo},{label:'Innovative Medicine ($M)',data:[13873,15202,15563,15763],borderColor:colors.teal,backgroundColor:'transparent',tension:0.3,pointRadius:5,pointBackgroundColor:colors.teal},{label:'MedTech ($M)',data:[8020,8541,8430,8801],borderColor:colors.orange,backgroundColor:'transparent',tension:0.3,pointRadius:5,pointBackgroundColor:colors.orange}]},options:{responsive:true,plugins:{legend:{position:'bottom',labels:{font:{family:'Inter',size:13},padding:16}},title:{display:true,text:'Quarterly Revenue Progression (FY2025)',font:{size:15,family:'Inter',weight:'600'},color:'#1a1a1a',padding:{bottom:14}}},scales:{y:{ticks:{callback:function(v){return '$'+v.toLocaleString()},font:{family:'Inter'}},grid:{color:'#f0f0f0'}},x:{grid:{display:false},ticks:{font:{family:'Inter'}}}}}});\nnew Chart(document.getElementById('stelaraChart'),{type:'bar',data:{labels:['STELARA Headwind','Reported IM Growth (Q3)','Underlying IM Growth (ex-STELARA)'],datasets:[{label:'Percentage Points',data:[-10.7,5.3,16.0],backgroundColor:[colors.red,colors.blue,colors.green],borderRadius:4}]},options:{responsive:true,indexAxis:'horizontal',plugins:{legend:{display:false},title:{display:true,text:'STELARA LOE Impact on Innovative Medicine Growth (Q3 2025)',font:{size:15,family:'Inter',weight:'600'},color:'#1a1a1a',padding:{bottom:14}}},scales:{y:{grid:{display:false},ticks:{font:{family:'Inter'}}},x:{ticks:{callback:function(v){return v+'%'},font:{family:'Inter'}},grid:{color:'#f0f0f0'}}}}});\nnew Chart(document.getElementById('outlookChart'),{type:'bar',data:{labels:['FY2023','FY2024','FY2025','FY2026 Target'],datasets:[{label:'Revenue ($ Billions)',data:[85.16,88.82,94.19,100],backgroundColor:[colors.slate,colors.blue,colors.indigo,'rgba(79,70,229,0.4)'],borderColor:['transparent','transparent','transparent',colors.indigo],borderWidth:[0,0,0,2],borderDash:[0,0,0,0],borderRadius:4}]},options:{responsive:true,plugins:{legend:{display:false},title:{display:true,text:'Johnson & Johnson Revenue Path to $100B',font:{size:15,family:'Inter',weight:'600'},color:'#1a1a1a',padding:{bottom:14}}},scales:{y:{beginAtZero:false,min:80,ticks:{callback:function(v){return '$'+v+'B'},font:{family:'Inter'}},grid:{color:'#f0f0f0'}},x:{grid:{display:false},ticks:{font:{family:'Inter'}}}}}});\n<\/script>\n\n\n\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &#038; Johnson reported $94.2B in FY2025 sales, marking 6% growth and its strongest-ever Q4 performance at $24.6B.<\/p>\n<p>The company is now targeting $100B+ annual revenue in FY2026, with full coverage of segment performance, key products, and pipeline trends heading into 2026.<\/p>\n","protected":false},"author":1,"featured_media":21825,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[245],"tags":[],"class_list":["post-21824","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-companies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Johnson &amp; Johnson Statistics 2026: Revenue Growth, Dividends And Workforce Data<\/title>\n<meta name=\"description\" content=\"Johnson &amp; Johnson reported $94.2B in FY2025 sales, marking 6% growth and its strongest-ever Q4 performance at $24.6B. The company is now targeting $100B+ annual revenue in FY2026, with full coverage of segment performance, key products, and pipeline trends heading into 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson &amp; Johnson Statistics 2026: Revenue Growth, Dividends And Workforce Data\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson reported $94.2B in FY2025 sales, marking 6% growth and its strongest-ever Q4 performance at $24.6B. The company is now targeting $100B+ annual revenue in FY2026, with full coverage of segment performance, key products, and pipeline trends heading into 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/\" \/>\n<meta property=\"og:site_name\" content=\"Quantumrun Foresight\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-18T11:56:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-18T11:57:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2026\/05\/johnson-johnson-statistics-e1779105376211.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"515\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Richard Jaimes\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Richard Jaimes\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/\"},\"author\":{\"name\":\"Richard Jaimes\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#\\\/schema\\\/person\\\/5a0afcb410d8e3137f58d5a201809011\"},\"headline\":\"Johnson &amp; Johnson Statistics 2026: Revenue Growth, Dividends And Workforce Data\",\"datePublished\":\"2026-05-18T11:56:31+00:00\",\"dateModified\":\"2026-05-18T11:57:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/\"},\"wordCount\":1135,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/johnson-johnson-statistics-e1779105376211.jpg\",\"articleSection\":[\"Companies\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/\",\"name\":\"Johnson &amp; Johnson Statistics 2026: Revenue Growth, Dividends And Workforce Data\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/johnson-johnson-statistics-e1779105376211.jpg\",\"datePublished\":\"2026-05-18T11:56:31+00:00\",\"dateModified\":\"2026-05-18T11:57:27+00:00\",\"description\":\"Johnson & Johnson reported $94.2B in FY2025 sales, marking 6% growth and its strongest-ever Q4 performance at $24.6B. The company is now targeting $100B+ annual revenue in FY2026, with full coverage of segment performance, key products, and pipeline trends heading into 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/johnson-johnson-statistics-e1779105376211.jpg\",\"contentUrl\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/johnson-johnson-statistics-e1779105376211.jpg\",\"width\":1024,\"height\":515,\"caption\":\"Infographic showing Johnson & Johnson 2025 financial performance and 2026 outlook, including revenue growth, segment breakdown, quarterly results, EPS, product highlights, and charts to $100B revenue target.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/johnson-johnson-statistics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Companies\",\"item\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/companies\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Johnson &amp; Johnson Statistics 2026: Revenue Growth, Dividends And Workforce Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#website\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/\",\"name\":\"Quantumrun Foresight\",\"description\":\"Thrive from future trends.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#organization\",\"name\":\"Quantumrun Foresight\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/cropped-con-logo-00.png\",\"contentUrl\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/cropped-con-logo-00.png\",\"width\":286,\"height\":55,\"caption\":\"Quantumrun Foresight\"},\"image\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#\\\/schema\\\/person\\\/5a0afcb410d8e3137f58d5a201809011\",\"name\":\"Richard Jaimes\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g\",\"caption\":\"Richard Jaimes\"},\"sameAs\":[\"https:\\\/\\\/www.quantumrun.com\\\/consulting\"],\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/author\\\/admin-stcons\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Johnson &amp; Johnson Statistics 2026: Revenue Growth, Dividends And Workforce Data","description":"Johnson & Johnson reported $94.2B in FY2025 sales, marking 6% growth and its strongest-ever Q4 performance at $24.6B. The company is now targeting $100B+ annual revenue in FY2026, with full coverage of segment performance, key products, and pipeline trends heading into 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/","og_locale":"en_US","og_type":"article","og_title":"Johnson &amp; Johnson Statistics 2026: Revenue Growth, Dividends And Workforce Data","og_description":"Johnson & Johnson reported $94.2B in FY2025 sales, marking 6% growth and its strongest-ever Q4 performance at $24.6B. The company is now targeting $100B+ annual revenue in FY2026, with full coverage of segment performance, key products, and pipeline trends heading into 2026.","og_url":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/","og_site_name":"Quantumrun Foresight","article_published_time":"2026-05-18T11:56:31+00:00","article_modified_time":"2026-05-18T11:57:27+00:00","og_image":[{"width":1024,"height":515,"url":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2026\/05\/johnson-johnson-statistics-e1779105376211.jpg","type":"image\/jpeg"}],"author":"Richard Jaimes","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Richard Jaimes","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/#article","isPartOf":{"@id":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/"},"author":{"name":"Richard Jaimes","@id":"https:\/\/www.quantumrun.com\/consulting\/#\/schema\/person\/5a0afcb410d8e3137f58d5a201809011"},"headline":"Johnson &amp; Johnson Statistics 2026: Revenue Growth, Dividends And Workforce Data","datePublished":"2026-05-18T11:56:31+00:00","dateModified":"2026-05-18T11:57:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/"},"wordCount":1135,"commentCount":0,"publisher":{"@id":"https:\/\/www.quantumrun.com\/consulting\/#organization"},"image":{"@id":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2026\/05\/johnson-johnson-statistics-e1779105376211.jpg","articleSection":["Companies"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/","url":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/","name":"Johnson &amp; Johnson Statistics 2026: Revenue Growth, Dividends And Workforce Data","isPartOf":{"@id":"https:\/\/www.quantumrun.com\/consulting\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/#primaryimage"},"image":{"@id":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2026\/05\/johnson-johnson-statistics-e1779105376211.jpg","datePublished":"2026-05-18T11:56:31+00:00","dateModified":"2026-05-18T11:57:27+00:00","description":"Johnson & Johnson reported $94.2B in FY2025 sales, marking 6% growth and its strongest-ever Q4 performance at $24.6B. The company is now targeting $100B+ annual revenue in FY2026, with full coverage of segment performance, key products, and pipeline trends heading into 2026.","breadcrumb":{"@id":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/#primaryimage","url":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2026\/05\/johnson-johnson-statistics-e1779105376211.jpg","contentUrl":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2026\/05\/johnson-johnson-statistics-e1779105376211.jpg","width":1024,"height":515,"caption":"Infographic showing Johnson & Johnson 2025 financial performance and 2026 outlook, including revenue growth, segment breakdown, quarterly results, EPS, product highlights, and charts to $100B revenue target."},{"@type":"BreadcrumbList","@id":"https:\/\/www.quantumrun.com\/consulting\/johnson-johnson-statistics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.quantumrun.com\/consulting\/"},{"@type":"ListItem","position":2,"name":"Companies","item":"https:\/\/www.quantumrun.com\/consulting\/companies\/"},{"@type":"ListItem","position":3,"name":"Johnson &amp; Johnson Statistics 2026: Revenue Growth, Dividends And Workforce Data"}]},{"@type":"WebSite","@id":"https:\/\/www.quantumrun.com\/consulting\/#website","url":"https:\/\/www.quantumrun.com\/consulting\/","name":"Quantumrun Foresight","description":"Thrive from future trends.","publisher":{"@id":"https:\/\/www.quantumrun.com\/consulting\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.quantumrun.com\/consulting\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.quantumrun.com\/consulting\/#organization","name":"Quantumrun Foresight","url":"https:\/\/www.quantumrun.com\/consulting\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.quantumrun.com\/consulting\/#\/schema\/logo\/image\/","url":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2020\/07\/cropped-con-logo-00.png","contentUrl":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2020\/07\/cropped-con-logo-00.png","width":286,"height":55,"caption":"Quantumrun Foresight"},"image":{"@id":"https:\/\/www.quantumrun.com\/consulting\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.quantumrun.com\/consulting\/#\/schema\/person\/5a0afcb410d8e3137f58d5a201809011","name":"Richard Jaimes","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g","caption":"Richard Jaimes"},"sameAs":["https:\/\/www.quantumrun.com\/consulting"],"url":"https:\/\/www.quantumrun.com\/consulting\/author\/admin-stcons\/"}]}},"_links":{"self":[{"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/posts\/21824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/comments?post=21824"}],"version-history":[{"count":2,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/posts\/21824\/revisions"}],"predecessor-version":[{"id":21827,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/posts\/21824\/revisions\/21827"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/media\/21825"}],"wp:attachment":[{"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/media?parent=21824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/categories?post=21824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/tags?post=21824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}